Recent Progress in CDK4/6 Inhibitors and PROTACs.

Area of Science:

• Molecular Biology
• Oncology
• Pharmacology

Background:

• Cell division is a fundamental eukaryotic process, tightly regulated by Cyclin-dependent kinases (CDKs).
• Aberrant CDK activation drives uncontrolled cell proliferation, a hallmark of cancer.
• Selective CDK4/6 inhibitors have emerged as effective therapies for ER-positive, HER2-negative breast cancer.

Purpose of the Study:

• To provide an in-depth analysis of CDK4/6 inhibitor mechanisms of action.
• To review recent advancements in CDK4/6 inhibitor development, including structural classifications.
• To explore novel proteolysis targeting chimeras (PROTACs) targeting CDK4/6.

Main Methods:

• Literature review of CDK4/6 inhibitors and PROTACs.
• Categorization of inhibitors based on structural characteristics and origin.
• Analysis of clinical success and mechanisms of action.

Main Results:

• CDK4/6 inhibitors represent a significant therapeutic advancement in oncology.
• Recent research focuses on diverse structural classes and origins of these inhibitors.
• PROTACs targeting CDK4/6 are an emerging area with therapeutic potential.

Conclusions:

• CDK4/6 inhibitors are crucial in treating specific breast cancer subtypes.
• Further research into CDK4/6 inhibitors and PROTACs holds promise for novel cancer therapies.
• Understanding inhibitor mechanisms and structures can guide future drug development.